Ischemic Optic Neuropathy from GCA

Update Item Information
Identifier 20190318_nanos_hottopic1_01_slides
Title Ischemic Optic Neuropathy from GCA
Creator Fiona Costello, MD
Affiliation Ottawa, Ontario, Canada
Subject Ischemic Optic Neuropathy (ION); Giant Cell Arteritis (GCA); Corticosteroids; Steroid Sparing Therapies; Tocilizumab
Description Giant cell arteritis (GCA) is a challenging condition to manage. Patients presenting with ION warrant special consideration, because their vision loss is often irreversible. In general terms, the neuroophthalmic care of these patients is governed by several universal goals, namely: preserving or improving the visual status of the patient; protecting the patient from non-visual consequences of the diagnosis; and, ameliorating the inevitable effects of high-dose, long term corticosteroid therapy. Yet, for any given patient there are also challenges that are case specific. Clinicians caring for these individuals must consider the relative frailty of the patient, and anticipate what co-morbidities may be unveiled or exacerbated by treatment. Moreover, the severity of the patient's vision loss, and presence or absence of non-visual manifestations also impact management decisions.
Date 2019-03
Language eng
Format application/pdf
Format Creation Microsoft PowerPoint
Type Text
Source 2019 North American Neuro-Ophthalmology Society Annual Meeting
Publisher Spencer S. Eccles Health Sciences Library, University of Utah
Holding Institution North American Neuro-Ophthalmology Association. NANOS Executive Office 5841 Cedar Lake Road, Suite 204, Minneapolis, MN 55416
ARK ark:/87278/s6v74t95
Context URL The NANOS Annual Meeting Neuro-Ophthalmology Collection: https://novel.utah.edu/collection/NAM/toc/
Setname ehsl_novel_nam
ID 1539211
Reference URL https://collections.lib.utah.edu/ark:/87278/s6v74t95
Back to Search Results